{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T03:45:52Z","timestamp":1777952752430,"version":"3.51.4"},"reference-count":44,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Xiamen Amoytop Biotech Co., Ltd","award":["\/"],"award-info":[{"award-number":["\/"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Aerosol Medicine and Pulmonary Drug Delivery"],"published-print":{"date-parts":[[2026,4,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>This study aimed to compare the pharmacokinetics and tissue distribution of aerosolized pegylated interferon \u03b1-2b (PEG IFN\u03b1-2b) with standard interferon \u03b1-2b (IFN\u03b1-2b) in an animal model, paving the way for further investigation into their pharmacodynamics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      Fifty-six Sprague Dawley rats were divided into 14 groups receiving either PEG IFN\u03b1-2b or standard IFN\u03b1-2b via aerosolized inhalation into the lower respiratory tract. Each group received a single dose of consistent concentration and volume. Pharmacokinetic parameters such as C\n                      <jats:sub>max<\/jats:sub>\n                      , T\n                      <jats:sub>max<\/jats:sub>\n                      , t\n                      <jats:sub>1\/2<\/jats:sub>\n                      , AUC\n                      <jats:sub>(0-t)<\/jats:sub>\n                      , and MRT\n                      <jats:sub>(0-t)<\/jats:sub>\n                      were evaluated through blood samples and tissue dissection at specified time intervals post-administration.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Analysis revealed significantly higher AUC\n                      <jats:sub>(0-t)<\/jats:sub>\n                      and MRT\n                      <jats:sub>(0-t)<\/jats:sub>\n                      in the lungs, trachea, and bronchi of the PEG IFN\u03b1-2b group compared to the standard IFN\u03b1-2b group (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt; 0.05), with minimal systemic exposure.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Aerosolized PEG IFN\u03b1-2b demonstrated increased drug exposure and retention in the lower respiratory tract compared to standard IFN\u03b1-2b, suggesting potential therapeutic advantages such as reduced dosing frequency. Further studies are warranted to explore enhanced clinical outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/19412711251370951","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T14:08:41Z","timestamp":1771510121000},"page":"95-103","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Exploratory Pharmacokinetic Study of Pegylated Interferon Alfa-2b Aerosolized Inhalation Administration"],"prefix":"10.1177","volume":"39","author":[{"given":"Hongran","family":"Chu","sequence":"first","affiliation":[{"name":"Biosteed Gene Expression Tech. Co., Ltd, Xiamen, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanzhou","family":"Wu","sequence":"additional","affiliation":[{"name":"Biosteed Gene Expression Tech. Co., Ltd, Xiamen, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fenfang","family":"Zou","sequence":"additional","affiliation":[{"name":"Xiamen Amoytop Biotech Co., Ltd, Xiamen, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7919-9571","authenticated-orcid":false,"given":"Yalin","family":"Yin","sequence":"additional","affiliation":[{"name":"Xiamen Amoytop Biotech Co., Ltd, Xiamen, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,8,20]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2017.1349609"},{"issue":"3","key":"e_1_3_4_3_2","first-page":"191","article-title":"Pharmacokinetics and tissue distribution of interferon \u03b12b (Pseudomonas putida) administered via atomization inhalation and intramuscular injection by 125 I labeling","volume":"39","author":"Yang C","year":"2015","unstructured":"Yang C, , Liu J, , Chu L. Pharmacokinetics and tissue distribution of interferon \u03b12b (Pseudomonas putida) administered via atomization inhalation and intramuscular injection by 125 I labeling. Int J Radiat Med Nucl Med., 2015; 39(3):191\u2013196.","journal-title":"Int J Radiat Med Nucl Med."},{"issue":"2","key":"e_1_3_4_4_2","first-page":"135","article-title":"Chinese Society of Clinical Pharmacy <Expert consensus on rational use of nebulized inhalation therapy> writing group, Expert consensus on rational use of nebulized inhalation therapy (2019)","volume":"38","year":"2019","unstructured":"Chinese Society of Clinical Pharmacy <Expert consensus on rational use of nebulized inhalation therapy> writing group, Expert consensus on rational use of nebulized inhalation therapy (2019). Herald of Medicine, 2019; 38(2):135\u2013146.","journal-title":"Herald of Medicine"},{"issue":"34","key":"e_1_3_4_5_2","first-page":"2696","article-title":"Chinese Society of Thoracic Society \u00abExpert consensus on the application of nebulized inhalation therapy in respiratory diseases\u00bb expert group. Expert consensus on the application of nebulized inhalation therapy in respiratory diseases","volume":"96","year":"2016","unstructured":"Chinese Society of Thoracic Society \u00abExpert consensus on the application of nebulized inhalation therapy in respiratory diseases\u00bb expert group. Expert consensus on the application of nebulized inhalation therapy in respiratory diseases. National Med J China, 2016; 96(34):2696\u20132708.","journal-title":"National Med J China"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.4187\/respcare.05624"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/icb.2012.9"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12950-020-00249-1"},{"issue":"1","key":"e_1_3_4_9_2","first-page":"1","article-title":"Biodistribution and metabolic pathway of Interferon-\u03b11b administered by aerosol inhalation in rabbits","volume":"31","author":"Liu J","year":"2013","unstructured":"Liu J, , Liu J, , Chu L, et al. Biodistribution and metabolic pathway of Interferon-\u03b11b administered by aerosol inhalation in rabbits. Herald of Medicine, 2013; 31(1):1\u20135.","journal-title":"Herald of Medicine"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.96.09010042"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1089\/jamp.2011.0919"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(94)00365-r"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-2600(20)30511-7"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri3581"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.24353"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri1961"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2018.06.004"},{"issue":"1","key":"e_1_3_4_18_2","first-page":"99","article-title":"Aerosolized interferon-alpha treatment in patients with multi-drug-resistant pulmonary tuberculosis","volume":"11","author":"Giosu\u00e8 S","year":"2000","unstructured":"Giosu\u00e8 S, , Casarini M, , Ameglio F, et al. Aerosolized interferon-alpha treatment in patients with multi-drug-resistant pulmonary tuberculosis. Eur Cytokine Netw, 2000; 11(1):99\u2013104.","journal-title":"Eur Cytokine Netw"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.158.4.9803065"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2009.05069.x"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2013.02.031"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/47.3.251"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2020.9350"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1177\/000348940511400608"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0148907"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1172\/jci126363"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14898"},{"issue":"16","key":"e_1_3_4_28_2","first-page":"1214","article-title":"Expert consensus on the clinical application of recombinant human interferon-\u03b11b in pediatrics","volume":"30","author":"Shen K","year":"2015","unstructured":"Shen K, , Zhang G, , Shang X. Expert consensus on the clinical application of recombinant human interferon-\u03b11b in pediatrics. Chin J Appl Clin Pediatr, 2015; 30(16):1214\u20131219.","journal-title":"Chin J Appl Clin Pediatr"},{"issue":"4","key":"e_1_3_4_29_2","first-page":"241","article-title":"Expert consensus on the diagnosis, treatment, and prevention of respiratory syncytial virus infection in children","volume":"35","author":"Shen K","year":"2020","unstructured":"Shen K, , Qian Y, , Xu W. Expert consensus on the diagnosis, treatment, and prevention of respiratory syncytial virus infection in children. Chin J Appl Clin Pediatr, 2020; 35(4):241\u2013250.","journal-title":"Chin J Appl Clin Pediatr"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12519-019-00277-9"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-020-06022-5"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200140070-00005"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.18.00632"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26648"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1086\/511042"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-11-165"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2893.2003.00450.x"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2015.06.023"},{"key":"e_1_3_4_39_2","volume-title":"Enzyme-Polyethylene Glycol Adducts: Modified Enzymes with Unique Properties","author":"Davis F","year":"1978","unstructured":"Davis F, , Abuchowski A, , Van E. Enzyme-Polyethylene Glycol Adducts: Modified Enzymes with Unique Properties. Springer US: Boston, MA; 1978."},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/9783527609628.ch15"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1056\/nejm200012073432301"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics6020333"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2014.03.012"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1021\/mp400091n"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.21635"}],"container-title":["Journal of Aerosol Medicine and Pulmonary Drug Delivery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/19412711251370951","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/19412711251370951","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/19412711251370951","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T13:15:35Z","timestamp":1777900535000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/19412711251370951"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,20]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4,1]]}},"alternative-id":["10.1177\/19412711251370951"],"URL":"https:\/\/doi.org\/10.1177\/19412711251370951","relation":{},"ISSN":["1941-2711","1941-2703"],"issn-type":[{"value":"1941-2711","type":"print"},{"value":"1941-2703","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,20]]}}}